Skip to main content
Premium Trial:

Request an Annual Quote

Tataa Biocenter to Distribute Strand's NGS Analysis Software in Europe

NEW YORK (GenomeWeb) – Tataa Biocenter and Strand Life Sciences have formed a strategic partnership, under which Tataa will distribute Strand's next-generation sequence data analysis software — Strand NGS — in Europe and also provide support for customers in that market.

Gӧteborg, Sweden-based Tataa also said that it will use Strand NGS, an integrated platform that offers tools for analyzing, managing, and visualizing NGS data, in its NGS training courses. Features of the platform include workflows for handling and analyzing DNA-seq, RNA-seq, small RNA-seq, ChIP-seq, and methyl-seq data; a browser tool for visualizing SNPs, insertions and deletions, large structural rearrangements, and more; and annotations for several standard organisms culled from various sources.

The partnership with Bangalore, India-based Strand enables Tataa to address customers' demands for comprehensive solutions that support their NGS workflows, Mikael Kubista, Tataa's president, said in a statement.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.